Maravai LifeSciences Holdings, Inc. (MRVI) Q1 2026 Earnings Call Transcript
Maravai LifeSciences NASDAQ: MRVI reported first-quarter fiscal 2026 results that management said marked a “strong start to 2026,” driven by growth at its TriLink segment, steady contribution from Cygnus, and the impact of restructuring actions taken last year.
Maravai LifeSciences Holdings, Inc. (MRVI) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to a loss of $0.08 per share a year ago.
Maravai LifeSciences (MRVI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Maravai LifeSciences Holdings, Inc. (MRVI) Q4 2025 Earnings Call Transcript
Maravai LifeSciences Holdings, Inc. (MRVI) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.06 per share a year ago.
Maravai LifeSciences Holdings, Inc. ( MRVI ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Debra Hart - Senior Director of Investor Relations Bernd Brust - CEO & Director Rajesh Asarpota - EVP & Chief Financial Officer Chanfeng Zhao - Senior VP & Chief Scientific Officer Conference Call Participants Justin Bowers - Deutsche Bank AG, Research Division Madeline Mollman - Wolfe Research, LLC Thomas Peterson - Robert W. Baird & Co. Incorporated, Research Division Nathan Bolanos - UBS Investment Bank, Research Division Matthew Stanton - Jefferies LLC, Research Division Presentation Operator Good afternoon, everyone.
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q2 2025 Earnings Conference Call August 11, 2025 5:00 PM ET Company Participants Bernd Brust - CEO & Director Debra Hart - Senior Director of Investor Relations Rajesh J. Asarpota - EVP & Chief Financial Officer Conference Call Participants Brandon Couillard - Wells Fargo Securities, LLC, Research Division Catherine Walden Ramsey Schulte - Robert W.
Maravai LifeSciences Holdings, Inc. (MRVI) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to break-even earnings per share a year ago.
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Debra Hart - Head, IR Kevin Herde - EVP and CFO Trey Martin - CEO Becky Buzzeo - EVP & CCO Conference Call Participants Conor McNamara - RBC Capital Markets Daniel Arias - Stifel Tejas Savant - Morgan Stanley Matthew Stanton - Jeffries Brandon Coulliard - Wells Fargo Matthew Hewitt - Craig-Hallum Operator Please stand by, we're about to begin. Good afternoon, everyone, and welcome to the Maravai LifeSciences Q1 2025 Results Earnings Call.
Maravai LifeSciences Holdings, Inc. (MRVI) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.02 per share a year ago.
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q4 2024 Earnings Conference Call March 20, 2025 5:00 PM ET Company Participants Deb Hart - Head, IR Kevin Herde - EVP and CFO Trey Martin - CEO Conference Call Participants Matt Stanton - Jeffries Doug Schenkel - Wolfe Research Matt Larew - William Blair Ricki Levitus - Guggenheim Tejas Savant - Morgan Stanley Dan Arias - Stifel Catherine Schulte - Baird Matt Sykes - Goldman Sachs Brandon Coulliard - Wells Fargo Anna Snopkowski - KeyBanc Capital Markets Operator Greetings. Welcome to Maravai LifeSciences Fourth Quarter 2024 Results Earnings Call.